This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Syph-Check Syphilis Antibody Point of Care (POC) Test (SyphPoc)

This study has been terminated.
(insufficient patient populations)
Information provided by (Responsible Party):
Healthcare Providers Direct, Inc. Identifier:
First received: August 8, 2008
Last updated: February 29, 2016
Last verified: February 2016
The study is designed to evaluate the performance of a rapid membrane test in a clinic or doctor's office setting to identify potential patients infected with syphilis and compare the results to currently licensed laboratory based tests.

Condition Intervention
Screening for Syphilis Infections Device: Syph-Check POC

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: One-Step Syphilis Point of Care Test for Rapid Immunoassay Screening of Antibodies to Treponema Pallidum

Resource links provided by NLM:

Further study details as provided by Healthcare Providers Direct, Inc.:

Primary Outcome Measures:
  • Identify the sensitivity and specificity of the POC test versus accepted laboratory tests [ Time Frame: end of study ]

Secondary Outcome Measures:
  • Percent positive agreement data will include supplemental test results identified by infection categories and treatment as possible [ Time Frame: end of study ]

Enrollment: 400
Study Start Date: March 2009
Study Completion Date: September 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
known syphilis infected patients
Device: Syph-Check POC
Rapid membrane test for syphilis antibodies
Other Names:
  • RPR
  • TPPA
  • syphilis
presumed uninfected patients
Device: Syph-Check POC
Rapid membrane test for syphilis antibodies
Other Names:
  • RPR
  • TPPA
  • syphilis

Detailed Description:
The overall objectives of this study are to determine the performance characteristics of a candidate rapid point-of-care test (Syph-Check cassette format) for Treponema pallidum antibodies in serum, plasma and finger stick whole blood obtained from females and males attending sexually transmitted diseases (STD) clinics, family planning / reproductive health clinics, and physician's office; and to compare the performance of this new, rapid test to currently licensed laboratory based tests, the non-treponemal RPR and a Treponemal ELISA or TPPA test.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Point of Care clinics and doctor's office that test routine patients (both male and female), i.e. STD clinics, planned parenthood, pre-marital, blood donors, pre-employment, and general populations from different geographic locations having varying prevalence populations.

Inclusion Criteria:

  • Men and Women will be eligible who:

    1. are 18 years of age or older;
    2. Routine "presumed uninfected" for screening visit, or show symptomatic signs of infection or are asymptomatic but are suspected of infection, and either/or have other STD disease conditions and infections, will be identified.
    3. Pregnant women in the first and third trimester

Exclusion Criteria:

  • are under 18 years of age
  • unwillingness to give consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00732355

United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Healthcare Providers Direct, Inc.
Study Director: Gary L Lehnus, Ph.D. Lehnus & Associates Consulting
  More Information

Responsible Party: Healthcare Providers Direct, Inc. Identifier: NCT00732355     History of Changes
Other Study ID Numbers: SY-101
Study First Received: August 8, 2008
Last Updated: February 29, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Healthcare Providers Direct, Inc.:

Additional relevant MeSH terms:
Treponemal Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Sexually Transmitted Diseases, Bacterial
Spirochaetales Infections
Sexually Transmitted Diseases
Genital Diseases, Male
Genital Diseases, Female
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017